Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
Open Access
Abstract
Introduction Gout affects 2.5% of the UK's adult population and is now the most common type of inflammatory arthritis. The long-term management of gout requires reduction of serum urate levels and this is most often achieved with use of xanthine oxidase inhibitors, such as allopurinol. Febuxostat is the first new xanthine oxidase inhibitor since allopurinol and was licensed for use in 2008. The European Medicines Agency requested a postlicensing cardiovascular safety study of febuxostat versus allopurinol, which has been named the Febuxostat versus Allopurinol Streamlined trial (FAST). Methods and analysis FAST is a cardiovascular safety study using the prospective, randomised, open, blinded endpoint design. FAST is recruiting in the UK and Denmark. Recruited patients are aged over 60 years, prescribed allopurinol for symptomatic hyperuricaemia and have at least one additional cardiovascular risk factor. After an allopurinol lead-in phase where the dose of allopurinol is optimised to achieve European League against Rheumatism (EULAR) urate targets (serum urate Ethics and dissemination FAST (ISRCTN72443728) has ethical approval in the UK and Denmark, and results will be published in a peer reviewed journal. Trial Registration number FAST is registered in the EU Clinical Trials Register (EUDRACT No: 2011-001883-23) and International Standard Randomised Controlled Trial Number Register (ISRCTN No: ISRCTN72443728).Keywords
This publication has 18 references indexed in Scilit:
- 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritisArthritis Care & Research, 2012
- Epidemiology of gout: An updateBest Practice & Research Clinical Rheumatology, 2010
- Uric Acid and Cardiovascular RiskNew England Journal of Medicine, 2008
- Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005Annals of the Rheumatic Diseases, 2008
- Serum Uric Acid and Risk of Cardiovascular Mortality: A Prospective Long-Term Study of 83 683 Austrian MenClinical Chemistry, 2008
- Guidelines for good pharmacoepidemiology practices (GPP)Pharmacoepidemiology and Drug Safety, 2008
- Serum uric acid is an independent predictor of all‐cause mortality in patients at high risk of cardiovascular disease: A preventive cardiology information system (PreCIS) database cohort studyArthritis & Rheumatism, 2008
- EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)Annals of the Rheumatic Diseases, 2006
- Record‐linkage for pharmacovigilance in ScotlandBritish Journal of Clinical Pharmacology, 1999
- Prospective Randomized Open Blinded End-point (PROBE) Study. A novel design for intervention trialsBlood Pressure, 1992